<DOC>
	<DOCNO>NCT03046134</DOCNO>
	<brief_summary>Chronic obstructive pulmonary disease ( COPD ) one lead cause morbidity mortality worldwide . By 2030 , COPD expect fourth main cause death . Community-acquired pneumonia ( CAP ) represent frequent complication also deadly cause COPD patient . Inhaled corticosteroid , frequently use among COPD patient increase risk pneumonia . The effect pneumococcal conjugate vaccine 13 ( PCV13 ) prevention pneumococcal pneumonia among COPD patient Korean population study yet . Several factor multi-lobar pneumonia , Pseudomonas aeruginosa pneumonia , high pneumonia severity relate poor outcome patient COPD pneumonia . Prior pneumococcal vaccine beneficial effect outcomes pneumonia COPD patient . However , effect pneumococcal vaccine clinical outcome COPD patient evaluate mainly 23-valent pneumococcal polysaccharide vaccine ( PPV23 ) . The beneficial effect PPV23 rapidly fade inoculation , prominent old age group . In sense , PPV23 vaccine sufficient prevent pneumococcal disease COPD patient COPD disease old age mortality rate increase exponentially advance age . Pneumococcal conjugate vaccine 13 ( PCV13 ) overcome wan phenomenon production memory B cell . Although PCV13 expect best option prevention pneumococcal pneumonia COPD patient , available study support . In study , conduct prospective , multi-center trial collaboration Korean pulmonologists five university-affiliated hospital . In study , evaluate influenza pneumococcal vaccination status , pathogen distribution , pneumonia severity , clinical outcome hospitalize pneumonia patient COPD . If successfully accomplish , study enhance awareness preventive use PCV13 COPD patient among Korean pulmonologists , importantly , lead protection COPD patient pneumococcal pneumonia , one frequent deadly complication .</brief_summary>
	<brief_title>Burden Hospitalized Pneumonia Korea COPD Population</brief_title>
	<detailed_description>1 . Objectives ; Prospective evaluation distribution pathogens clinical characteristic hospitalize pneumonia patient COPD 2 . SUBJECTS AND CENTERS A . Subjects ; COPD patient hospitalize community-acquired pneumonia Feb , 2017 Feb , 2018 . B . Centers ; More five university-affiliated hospital Korea 3 . OTHER THERAPY ; Treatment COPD pneumonia do disposal attend physician hospital . 4 . STUDY DESIGN ; prospective , multi-center , cohort study 5 . STUDY ANALYSIS A . The required number COPD patient hospitalize community-acquired pneumonia - The sample size calculation base detect 1 point difference CURB-65 score influenza/pneumococcal vaccine recipient non-recipients ( expect mean CURB-65 score 3 point influenza/pneumococcal vaccine recipient 4 point non-recipients ) , assume common standard deviation 1 point group , * two-tailed test 5 % type I error , desire power 80 % . In term PCV 13 , estimate sample size independent t-test 90 expect 10 % PCV13 recipients 90 % non-recipients ( Korea , 10 % candidate estimate vaccinated PCV13 ) . Since CURB-65 score may symmetrically distribute , add 15 % require number consider non-parametric test desire number patient COPD pneumococcal pneumonia 104 analysis . Total 384 COPD patient admit community-acquired pneumonia enrol , assume 30 % prevalence pneumococcal pneumonia among ( prevalence pneumococcal pneumonia 25~45 % Korea ) , allowance 10 % possible data loss . - referenced 'Role Semi-quantitative Serum Procalcitonin Assessing Prognosis Community Acquired Bacterial Pneumonia Compared PORT PSI , CURB-65 CRB-65 Journal Clinical Diagnostic Research . 2015 Jul , Vol-9 ( 7 ) : OC01-OC04 ' B. Parameters evaluate A ) Demographic data . Age , gender , BMI , smoke status , socioeconomic status B ) Past medical history . Comorbidities ; diabetes , hypertension , malignancy , chronic renal disease , chronic liver disease… . Smoking status amount smoke pack-year . Vaccination status ( type time ) - Will check history take review medical record - PCV13 , PPV23 , Influenza vaccine , Zostavax… . C ) Diagnostic test identification pneumonia pathogen . Sputum Gram stain/culture ( adequacy evaluate Bartlett criterion ) - Sputum PCR test bacterial pneumonia pathogens - Multiplex PCR test design detection S. pneumoniae , M. pneumoniae , L. pneumophila , H. influenza , B. pertussis , C. pneumoniae - Urine antigen test ( Binax SS-UAD ) pneumococcus - two aliquot urine sample frozen store subsequent shipment central laboratory ( Pfizer Vaccines Research East Early Development , Pearl River , PA , USA ) Luminex platform-based multiplex UAD assay test describe previously ( Pride et al . Clin Vaccine Immunol 2012 ; 19:1131-41 ) . Processing , store ship urine sample carry accord Pfizer protocol . Urine test locally use commercially-available BinaxNOW® S. pneumoniae antigen test also . - Control urine sample collect 400 adult without pneumonia accord Pfizer urine collect method store subsequent shipment central laboratory ( Pfizer Vaccines Research East Early Development , Pearl River , PA , USA ) Luminex platform-based multiplex UAD assay test . - Two set blood culture D ) Severity score - Pneumonia severity index ( PSI ) - CURB-65 E ) Outcome parameter - ICU admission rate - Mechanical ventilation rate - ICU stay hospital stay - Mortality 6 . SAFETY ; ; This observational study evaluate effect previously inoculate influenza/pneumococcal vaccine . Treatment pneumonia COPD do attend physician disposal . In set would ethical issue debate . 7 . DECISION POINTS/ STATISTICAL METHODS/INTERIM ANALYSIS ; The statistic purely descriptive . Continuous variable present mean ± SD median value minimum maximum value . Categorical data present frequency percentile . Intergroup comparison continuous variable do student T test categorical data do Chi-square test Fisher 's exact test . Statistical significance determine 5 % level . We consider non-parametric equivalent test distributional assumption suitably make . 8 . DATES ; Feb 2017 ~ FEB 2018</detailed_description>
	<mesh_term>Pneumonia</mesh_term>
	<criteria>Inclusion Criteria COPD : Currently smoke male female 40 year . Smoking history ≥ 10 packyears . Post bronchodilator ( BD ) FEV1/FVC &lt; 70 % post BD FEV1 &lt; 80 % predict . Exclusion Criteria COPD Chest radiologic abnormality ( take development pneumonia ) explain obstructive pattern pulmonary function . Current diagnosis bronchial asthma . Inclusion criterion communityacquired pneumonia Newly develop pneumonic infiltrates ( lobar , broncho , interstitialpattern ) chest radiography ( take development respiratory symptom ) least 2 follow 3 criterion Body temperature ( &lt; 36℃ ≥ 38.0℃ ) White blood cell count ( &lt; 5,000/mm3 &gt; 10,000/mm3 ) Cough and/or sputum</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>